Washington Trial Tests GLP-1 Drug for Alcohol Cravings

A new clinical trial in Washington state is testing whether a GLP-1 medication can help people with moderate to severe alcohol use disorder drink less.

The study points to a broader shift in alcohol recovery, where medication-assisted treatment is expanding beyond the detox stage into long-term craving management.

What the University of Washington Is Studying

UW Medicine is the only Pacific Northwest site in a 30-site Phase 3 trial of brenipatide, a novel GLP-1/GIP drug.

The 14-month study enrolls adults ages 18 to 75, and all participants will eventually receive either the investigational drug or a placebo in a double-blind design, meaning neither patients nor researchers know who is getting which.

The site has already met its enrollment target. The primary goal is to learn whether brenipatide beats placebo at reducing alcohol cravings and heavy drinking.

Dr. Mark Duncan, an addiction psychiatrist and the site’s principal investigator, called it an exciting prospect and said early research suggests these medications could offer a powerful new option for alcohol use disorder.

Mary Hatch, an addiction psychologist and site co-investigator, said part of the appeal is accessibility, because a primary care provider could offer a medication people already recognize, rather than requiring inpatient rehab as the only entry point.

How GLP-1 Drugs May Affect Drinking

GLP-1 medications are widely known for weight loss, diabetes, and cardiovascular benefits. Early evidence suggests they may also curb addiction by acting on the brain’s mesolimbic pathway, the reward-and-desire circuitry that drives craving and reinforcement.

Researchers are studying the same class for opioid and nicotine use as well. Because this is still under study, the findings are best read as promising rather than proven, and brenipatide is not FDA-approved for alcohol use disorder.

Where This Fits in Alcohol Detox and Recovery

This is an important distinction for anyone researching detox. Brenipatide is being tested to reduce cravings and drinking, not to manage acute alcohol withdrawal.

Alcohol withdrawal can be life-threatening, with risks that include seizures and delirium tremens, so medical detox remains the safe standard for anyone physically dependent on alcohol.

A craving-reduction medication would come into play in the recovery phase that follows detox, as a tool to help prevent a return to heavy drinking.

Understanding Medication-Assisted Treatment for Alcohol

Medication-assisted treatment, or MAT, combines FDA-approved medications with counseling and support. For alcohol use disorder, approved options already include naltrexone, acamprosate, and disulfiram.

A GLP-1 drug, if trials succeed, could eventually add to that toolkit. What separates MAT from unproven detox products and cleanses is exactly what this trial represents, which is controlled, evidence-based research measured against placebo.

Finding Medical Detox

If you or someone you love is dependent on alcohol, never attempt withdrawal alone, because alcohol and benzodiazepine withdrawal can be dangerous without medical oversight.

Detox.com’s directory can help you find medically supervised detox programs and understand how medication-assisted treatment supports recovery after detox. Call 800-996-6135(Sponsored) to learn more about